Processa Pharmaceuticals Inc (NAS:PCSA)

$ 1.96 -0.04 (-2%) Market Cap: 5.60 Mil Enterprise Value: -3.18 Mil PE Ratio: 0 PB Ratio: 0.63 GF Score: 30/100

Processa Pharmaceuticals Inc at EBD Group Biotech Showcase Transcript
Jan 09, 2024
Processa Pharmaceuticals Inc Fireside Chat Transcript
Dec 20, 2023
Processa Pharmaceuticals Inc at ThinkEquity Conference Transcript
Oct 19, 2023
Q4 2022 Processa Pharmaceuticals Inc Earnings Call Transcript
Mar 30, 2023

$9.6 (+5.63%)

Earnings
Processa Pharmaceuticals Inc at EBD Group Biotech Showcase Transcript
Jan 11, 2023
Q3 2022 Processa Pharmaceuticals Inc Earnings Call Transcript
Nov 08, 2022

$43 (+1.90%)

Earnings
Processa Pharmaceuticals Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 14, 2022
Q2 2022 Processa Pharmaceuticals Inc Earnings Call Transcript
Aug 11, 2022

$62.9 (-2.78%)

Earnings
Q1 2022 Processa Pharmaceuticals Inc Earnings Call Transcript
May 12, 2022

$39 (+8.94%)

Earnings
Q3 2021 Processa Pharmaceuticals Inc Earnings Call Transcript
Nov 11, 2021

$142.4 (+3.64%)

Earnings
Q2 2021 Processa Pharmaceuticals Inc Earnings Call Transcript
Aug 12, 2021

$117 (+1.39%)

Earnings
Q1 2021 Processa Pharmaceuticals Inc Earnings Call Transcript
May 13, 2021

$123.2 (-0.81%)

Earnings
Q3 2020 Processa Pharmaceuticals Inc Earnings Call Transcript
Nov 12, 2020

$84.2 (-0.94%)

Earnings

Q1 2022 Processa Pharmaceuticals Inc Earnings Call Transcript

May 12, 2022 / 08:30PM GMT

Release Date Price: $39 (+8.94%)

Transcript 10-Q

Operator

Greetings and welcome to Processa Pharmaceuticals' first-quarter 2022 earnings conference call and corporate update. (Operator Instructions) As a reminder, this conference is being recorded.

It is now my pleasure to introduce Jim Stanker, Chief Financial Officer. Thank you, sir. You may begin.

Jim Stanker

Processa Pharmaceuticals, Inc. - CFO

Thank you and welcome to Processa's first-quarter 2022 results and drug development update conference call. Joining me on the call today are our Chief Executive Officer, Dr. David Young; and our Chief Operating Officer, Mike Floyd.

Shortly before this call, we filed our first-quarter 2022 Form 10-Q. I want to remind everyone that a PowerPoint presentation will accompany Dr. Young's prepared remarks. To view the PowerPoint slides, please go to the investor relations section of the company's website or to our earnings press release and then click on the webcast link to follow along.

I will start our call by reading the Safe Harbor statement. This statement is made pursuant to the Safe Harbor for

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.